

# AHA HIGHLIGHTS

2025

**HOSTED LIVE ON:  
MONDAY, DECEMBER 8, 2025**

Developed by:



## SPEAKERS

### Program Overview:

This program covered key clinical trial findings and their implications from AHA 2025. This program is intended for cardiovascular specialists and primary care physicians.

### Discussion Topics:

What's new in resistant hypertension?

What is the role of dual agonist treatment on heart failure outcomes in patients with ASCVD and DM?

How effective is an oral PCSK9 inhibitor in patients with ASCVD or FH?

Can we prevent pancreatitis through triglyceride lowering?

Is there a role for PCSK9 inhibition in primary prevention or patients without events?

### Learning Objectives:

Following participation in this program, participants will be able to:

- Identify the clinical implications of the new data presented at AHA 2025
- Examine where the data presented may impact clinical practice guidelines
- Apply the latest evidence-based strategies in clinical practice



**Milan Gupta**

MD, FRCPC, FCCS, CPC(HC)

Assistant Professor,  
Department of Medicine,  
University of Toronto  
Medical Director,  
Collaborative CME & Research Network  
Brampton, ON



**Narendra Singh**

MD, FRCPC, FCCS, FACC, FAHA

Director, NSC Cardiology Clinical  
Assistant Professor,  
Medical College of Georgia at Augusta  
University and Mercer University  
Atlanta, GA



Visit: [www.ccrnmd.com](http://www.ccrnmd.com)

For inquiries regarding this program, please contact [info@ccrnmd.com](mailto:info@ccrnmd.com)

This program was developed by CCRN and has received unrestricted educational funding from Amgen, AstraZeneca, Lilly, and Merck.